Dawn F. Ionescu
YOU?
Author Swipe
View article: Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II)
Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II) Open
Purpose To assess the effect of esketamine nasal spray on patient-reported outcomes (PROs) in patients with major depressive disorder having active suicidal ideation with intent (MDSI). Methods Patient-level data from two phase 3 studies (…
View article: Biomarkers in mood disorders research: developing new and improved therapeutics
Biomarkers in mood disorders research: developing new and improved therapeutics Open
Background Recently, surrogate neurobiological biomarkers that correlate with target engagement and therapeutic response have been developed and tested in early phase studies of mood disorders. Objective The identification of biomarkers co…
View article: Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior
Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior Open
Purpose/Background Numerous health authority approvals of esketamine nasal spray, combined with oral antidepressant, to treat depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior were based o…
View article: The effect of esketamine in patients with treatment‐resistant depression with and without comorbid anxiety symptoms or disorder
The effect of esketamine in patients with treatment‐resistant depression with and without comorbid anxiety symptoms or disorder Open
Post hoc data support efficacy of esketamine plus an oral antidepressant in patients with TRD, regardless of comorbid anxiety.
View article: Monitoring Changes in Depression Severity Using Wearable and Mobile Sensors
Monitoring Changes in Depression Severity Using Wearable and Mobile Sensors Open
Background: While preliminary evidence suggests that sensors may be employed to detect presence of low mood it is still unclear whether they can be leveraged for measuring depression symptom severity. This study evaluates the feasibility a…
View article: Studying pre-treatment and ketamine-induced changes in white matter microstructure in the context of ketamine’s antidepressant effects
Studying pre-treatment and ketamine-induced changes in white matter microstructure in the context of ketamine’s antidepressant effects Open
Ketamine is increasingly being used as a therapeutic for treatment-resistant depression (TRD), yet the effects of ketamine on the human brain remain largely unknown. This pilot study employed diffusion magnetic resonance imaging (dMRI) to …
View article: Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)
Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II) Open
Background Patients with major depressive disorder (MDD) having active suicidal ideation with intent require immediate treatment. Methods This double-blind study (ASPIRE II) randomized adults (aged 18–64 years) with MDD having active suici…
View article: Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent
Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent Open
ClinicalTrials.gov identifier: NCT03039192.
View article: The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder
The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder Open
Background: This study sought to reproduce, in a larger sample, previous findings of a correlation between smaller raw 3-Tesla (3T) hippocampal volumes and improved antidepressant efficacy of ketamine in individuals with major depressive d…
View article: The Role of Chronic Stress in Anxious Depression
The Role of Chronic Stress in Anxious Depression Open
Depression is a heterogeneous disease with many different subtypes. Patients with the anxious depression—a common subtype of major depression—are at an increased risk for treatment-resistance to standard antidepressants, with resultant inc…
View article: Ziprasidone augmentation for anxious depression
Ziprasidone augmentation for anxious depression Open
Previously, we found an anxiolytic effect of ziprasidone augmentation to escitalopram (compared with placebo augmentation) in patients with depression in an 8-week, randomized, double-blind, parallel-group, placebo-controlled trial. Here, …